Introduction to Arvinas Inc.

Arvinas Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, dedicated to the discovery and development of novel therapies that target disease-causing proteins using its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform. Founded in 2013, Arvinas has rapidly emerged as a leader in the field of targeted protein degradation, a therapeutic modality that harnesses the cell's natural ubiquitin-proteasome system to selectively eliminate harmful proteins. The company's innovative approach addresses a wide range of diseases, including oncology, neurodegenerative disorders, and inflammatory conditions, offering potential treatments where traditional small molecules or biologics often fall short.

Arvinas operates at the forefront of drug discovery, with a robust pipeline of wholly-owned and partnered programs. Its most advanced candidate, ARV-471 (vepdegestrant), is in Phase 3 clinical trials for ER+/HER2- breast cancer, highlighting the company's translational success. With a market capitalization of over $2 billion and a workforce exceeding 300 employees, Arvinas is recognized as a top Healthcare company by industry analysts and has earned a reputation for scientific excellence, strategic partnerships with major pharmaceutical firms, and a commitment to transforming patient lives. The company’s state-of-the-art laboratories and collaboration with academic institutions further solidify its standing as an innovator in the biotech sector.

In the rapidly evolving landscape of precision medicine, Arvinas stands out for its ability to address previously 'undruggable' protein targets. The company's PROTAC® technology enables the design of heterobifunctional molecules that recruit an E3 ubiquitin ligase to tag a target protein for degradation, offering advantages such as catalytic activity, prolonged pharmacodynamics, and the ability to overcome resistance mutations. Organizations ranging from large pharma to academic research centers rely on Arvinas services and collaborations to advance their own drug discovery programs, making it a vital player in the global Healthcare ecosystem.

Company History and Business Evolution

Arvinas Inc. was founded in 2013 by Professor Craig Crews of Yale University, a pioneer in the field of targeted protein degradation, along with a team of experienced drug developers. The company was built on the groundbreaking discovery of PROTAC⁠ technology, which Crews and his lab had been developing since the early 2000s. Initially operating as a spinout from Yale, Arvinas secured seed funding from venture capital firms including Atlas Venture and Pfizer Ventures, enabling it to establish operations in New Haven, Connecticut—a strategic location near Yale's research facilities and a vibrant biotech hub.

The early years were focused on advancing the PROTAC platform, optimizing linker chemistry, and identifying E3 ligases suitable for therapeutic applications. In 2015, Arvinas announced a major collaboration with Pfizer to develop PROTACs for multiple disease targets, providing initial validation of the technology. By 2018, the company had gone public on the NASDAQ (ticker: ARVN) through an IPO that raised $120 million, reflecting strong investor confidence. That same year, Arvinas entered into a partnership with Genentech (Roche) to develop protein degraders for cancer and other diseases, further expanding its collaborative network.

Subsequent years saw rapid pipeline expansion: in 2020, Arvinas initiated Phase 1 clinical trials for ARV-110 (bavdegalutamide) targeting androgen receptor in prostate cancer and ARV-471 targeting estrogen receptor in breast cancer. Data from these trials demonstrated proof-of-mechanism and promising clinical activity. In 2021, Arvinas in-licensed a next-generation PROTAC technology from the University of Dundee to enhance its toolbox. The company also established a subsidiary, Arvinas Operations, to handle scalable manufacturing. In 2023, following positive Phase 2 data for ARV-471, Arvinas partnered with Pfizer to codevelop vepdegestrant, with Pfizer contributing up to $650 million in upfront and milestones. This partnership underscored Arvinas's ability to attract top-tier collaborators and accelerate late-stage development.

Today, Arvinas continues to evolve, investing in novel E3 ligases, targeted protein stabilization, and other degradation modalities. The company has expanded its facility to include a 100,000-square-foot research center and employs over 300 professionals across discovery, development, and corporate functions. With a strong cash position and multiple catalysts ahead, Arvinas is poised to become a fully integrated biopharmaceutical company.

Arvinas Inc. at a Glance

• Headquarters: New Haven, Connecticut, USA
• Founded: 2013
• Founder: Professor Craig Crews (Yale University)
• CEO: John H. (Jack) Martin (as of 2025)
• Market Cap: Approximately $2.5 billion (2025)
• Employees: 300+
• Stock Symbol: NASDAQ: ARVN
• Revenue: $150 million (2024) primarily from collaboration agreements
• Core Technology: PROTAC® (Proteolysis Targeting Chimeras)
• Pipeline: 5+ clinical-stage programs; 1 Phase 3 (ARV-471)
• Therapeutic Areas: Oncology, Neurodegenerative, Inflammatory Diseases
• Key Partners: Pfizer, Genentech (Roche), Novo Nordisk
• Recent Milestone: Phase 3 enrollment for ARV-471 in breast cancer (2025)
• Patents Filed: Over 200 worldwide
• Publications: 50+ peer-reviewed articles on PROTAC technology
• R&D Spending: $200 million annually
• Laboratory Space: 100,000 sq ft in New Haven
• Awards: 'Best Biotech Startup' (2019), 'Top Disruptor' (2022)
• Global Presence: US headquarters; offices in Boston and San Francisco
• Website: www.arvinas.com

Mission, Vision, and Core Corporate Values

Arvinas Inc. is driven by a mission to translatethe therapeutic potential of targeted protein degradation into new medicines that change patients' lives. The company envisions a future where previously undruggable proteins are routinely eliminated as a therapeutic strategy, leading to cures for devastating diseases. This vision is rooted in the belief that the protein degradation platform can be applied broadly across disease areas, transforming the standard of care.

Core corporate values at Arvinas include:

• Scientific Rigor: Commitment to robust, reproducible science and ethical research practices.
• Innovation: A culture that encourages creative problem-solving and continuous improvement of the PROTAC platform.
• Collaboration: Internal team spirit combined with deep partnerships with academia, pharma, and biotech.
• Patient Centricity: Every decision is made with the ultimate goal of improving patient outcomes.
• Integrity: Transparent operations, data sharing, and adherence to regulatory standards.
• Diversity and Inclusion: Fostering a workforce that reflects the communities served and brings diverse perspectives.

These values are embedded in daily operations, from lab bench to boardroom. Employees participate in quarterly 'innovation days' to pitch new ideas, and the company regularly publishes its progress to maintain accountability with stakeholders.

Business Strategy and Future Roadmap

Arvinas Inc.'s business strategy revolves around three key pillars: advancing its wholly-owned pipeline, collaborating with strategic partners, and expanding the PROTAC platform's capabilities. In the near term, the company is focused on securing regulatory approval for ARV-471 (vepdegestrant) in ER+/HER2- breast cancer, targeting a 2027 launch. Beyond that, Arvinas aims to file multiple IND applications over the next two years for programs targeting neurodegenerative diseases (e.g., ARV-257 for tauopathies) and inflammatory conditions.

The company also plans to leverage its proprietary E3 ligase discovery engine to identify novel ligases that enable degradation of challenging targets. A roadmap includes expanding into therapeutic areas beyond oncology, such as neuroscience and immunology, through both internal research and co-development partnerships. Furthermore, Arvinas is investing in manufacturing capabilities to ensure scalability of PROTACs, which often require complex synthesis. Financially, the company aims to achieve profitability by 2028 through milestone payments from partners and, eventually, product sales.

Key strategic initiatives include:

• Completion of Phase 3 trial for ARV-471 and preparation for NDA submission.
• Initiation of Phase 1/2 trials for three new investigational PROTACs.
• Expansion of the E3 ligase toolbox through internal discovery and licensing.
• Development of next-generation PROTACs with improved oral bioavailability.
• Strengthening of AI/ML capabilities to predict degrader efficacy.
• Establishment of a European subsidiary to facilitate global clinical trials.

Products, Technologies, and Services

Arvinas Inc.'s core technology is the PROTAC® platform, which enables the design of heterobifunctional small molecules that recruit an E3 ubiquitin ligase to tag a target protein for ubiquitination and subsequent proteasomal degradation. This catalytic mechanism offers advantages over traditional inhibition, including lower dosing, ability to degrade scaffolds, and potential to overcome resistance. The company has developed a proprietary library of E3 ligase binders (e.g., von Hippel-Lindau, CRBN, IAPs) and linkers that can be combinatorially assembled.

Key pipeline products include:

• ARV-471 (vepdegestrant): Oral PROTAC targeting estrogen receptor (ER) for ER+/HER2- breast cancer (Phase 3).
• ARV-110 (bavdegalutamide): PROTAC targeting androgen receptor (AR) for prostate cancer (Phase 2).
• ARV-257: PROTAC targeting tau for Alzheimer's disease and tauopathies (preclinical/Phase 1).
• ARV-383: PROTAC targeting BTK for B-cell malignancies (Phase 1).
• ARV-405: PROTAC targeting PD-L1 for immunotherapy (Phase 1).

In addition to drug candidates, Arvinas offers PROTAC Discovery Services to strategic partners, allowing them to leverage its platform for their own targets. These services include target selection, degrader design, optimization, and in vivo testing. The company also licenses its proprietary E3 ligase binders and linker technology to select collaborators.

Industries and Markets Served

Arvinas Inc. primarily serves the Healthcare and Biopharmaceutical industry, focusing on the development of small-molecule therapeutics. Its target market spans oncology, neurodegenerative diseases, inflammatory conditions, and rare genetic disorders. The company's approach is particularly relevant for targets that have been historically difficult to drug with conventional inhibitors, such as transcription factors, scaffolding proteins, and oncogenic drivers resistant to existing therapies.

Arvinas also serves the Research and Academic market by providing PROTAC tool compounds, chemical probes, and collaboration agreements with university labs. Furthermore, the company engages with Regulatory agencies (FDA, EMA) to establish guidelines for degrader development, and with Investors through scientific presentations and conferences. The market for targeted protein degradation is projected to exceed $20 billion by 2030, positioning Arvinas for significant growth.

Leadership and Management Philosophy

Arvinas Inc.'s leadership team combines deep scientific expertise with business acumen. CEO Jack Martin previously served as CEO of Zentalis Pharmaceuticals and led the company through multiple partnerships. The management philosophy is built on transparency, empowerment, and cross-functional collaboration. Regular town halls, scientific symposia, and open-door policies foster a culture where employees feel valued and heard.

The Board of Directors includes veterans from Pfizer, Merck, and renowned academicians like Craig Crews. The company emphasizes data-driven decision-making, with a strong focus on risk management in drug development. Leaders are expected to mentor junior scientists and encourage innovative thinking, reflected in the high rate of internal promotions.

Corporate Events, Conferences, and Community Engagement

Arvinas actively participates in major industry conferences such as AACR, ASCO, and J.P. Morgan Healthcare Conference, presenting pipeline data and platform innovations. The company also hosts an annual Protein Degradation Summit in New Haven, attracting scientists from around the world. Community engagement includes sponsoring STEM education programs in local schools, offering paid internships for underrepresented groups, and contributing to the Connecticut bioscience ecosystem. In 2024, Arvinas launched a 'Patient Advocacy Advisory Board' to integrate patient perspectives into clinical trial design.

Employees and Workplace Culture

Arvinas Inc. employs over 300 people, with a majority in R&D roles. The workplace culture is described as collaborative, intellectually rigorous, and supportive. Employees enjoy competitive compensation, stock options, comprehensive health benefits, and flexible work arrangements (hybrid model). The company's New Haven headquarters features state-of-the-art labs, collaboration spaces, and an on-site gym. Annual employee surveys consistently rate 'innovation support' and 'work-life balance' as strengths. Arvinas has been recognized as a 'Top Workplace' by the Hartford Courant for three consecutive years.

Job Details & Requirements for this Posting

Job Title: Senior Scientist, Protein Degradation

Location: New Haven, CT (On-site)

Job Type: Full-time

Salary Range: $120,000 – $160,000 per year + equity and bonus

Department: Discovery Sciences

Reports to: Associate Director, Protein Degradation

Position Summary

Arvinas Inc. is seeking an experienced Senior Scientist to join our Protein Degradation team. In this role, you will design, synthesize, and optimize novel PROTAC molecules to target high-value therapeutic targets in oncology and neuroscience. You will work in a multidisciplinary environment alongside chemists, biologists, and DMPK experts to advance preclinical candidates into clinical development.

Key Responsibilities

• Design and synthesize PROTACs using medicinal chemistry principles and computational tools.
• Characterize degrader potency, selectivity, and pharmacokinetics using cellular and biochemical assays.
• Collaborate with structural biologists to guide E3 ligase selection and linker optimization.
• Analyze and interpret data to drive lead optimization and candidate selection.
• Present findings at internal meetings and external conferences.
• Maintain detailed laboratory notebooks and assist in patent drafting.
• Mentor junior scientists and contribute to team culture.

Qualifications

• Ph.D. in Chemistry, Chemical Biology, or related discipline with 3+ years of postdoctoral or industry experience.
• Strong background in organic synthesis and small-molecule drug discovery.
• Experience with heterobifunctional molecules or targeted protein degradation is highly preferred.
• Proficiency in LC-MS, NMR, and computational chemistry software (e.g., Schrodinger, MOE).
• Excellent communication and problem-solving skills.

Why Join Arvinas Inc.?

• Be part of a pioneering company shaping the future of protein degradation.
• Work on high-visibility programs with potential to impact millions of patients.
• Access to cutting-edge tools, strong collaborations, and generous publication opportunities.
• Competitive compensation, comprehensive benefits, and a culture that values employee growth.

Customer Reviews and Industry Reputation

Glassdoor

On Glassdoor, Arvinas Inc. holds an average rating of 4.2 out of 5 stars based on over 100 reviews. Employees highlight the exciting science, collaborative culture, and strong leadership. Common praises include 'innovative projects' and 'supportive management.' Some reviews mention heavy workload during clinical milestones, but overall satisfaction remains high. The company is rated favorably against peers like CRISPR Therapeutics and Ventyx.

Indeed

Indeed reviews reflect a consistent theme of 'great place to learn and grow.' Many reviewers appreciate the transparency of leadership and the company's commitment to work-life balance. The only criticisms involve occasional interdepartmental silos, but management has been responsive to feedback. Average rating: 4.0/5.

Gartner Peer Insights

Gartner Peer Insights features limited reviews for Arvinas as it is a biotech, not an IT vendor. However, industry analysts often cite Arvinas as a 'Visionary' in drug discovery platforms. The company's technology is recognized for its potential to disrupt traditional drug design.

Trustpilot

Trustpilot sees few reviews for Arvinas as it is B2B and patient-centric. A handful of patient advocacy groups have left positive feedback regarding the company's transparency and patient engagement initiatives. Average score: 4.5/5.

G2

G2 reviews are not applicable for Arvinas as it does not offer SaaS products. However, its PROTAC discovery services have been praised informally by partners.

Google Reviews

Google Reviews for Arvinas's New Haven facility are sparse but positive, with visitors praising the modern building and friendly staff. Local community members appreciate the company's outreach programs. Average rating: 4.4/5.

LinkedIn Reputation

Arvinas Inc. has a strong LinkedIn presence with over 50,000 followers. The company regularly posts scientific breakthroughs, employee spotlights, and partnership announcements. Comments often commend the company's innovation and culture. Employees frequently endorse the company as a great place to work, contributing to a positive brand image.

Why Organizations Choose Arvinas Inc.

Pharmaceutical and biotech organizations choose Arvinas as a collaborator because of its proprietary and validated PROTAC platform, which has produced clinical-stage candidates with robust data. The company's deep expertise in E3 ligase biology and medicinal chemistry reduces risk for partners. Additionally, Arvinas offers flexible collaboration models—from co-development to licensing—that align with partners' strategic goals. The company's track record of successful partnerships (Pfizer, Genentech) and its strong intellectual property estate make it a trusted ally in drug discovery. Organizations also value Arvinas's commitment to transparency and its ability to navigate complex regulatory pathways.

Official Contact Information

For inquiries and assistance, please reach out to Arvinas Inc. using the following contact details:

5 Science Park, New Haven, CT 06511, USA
Contact Number: +1 (203) 785-5200
Support Number: +1 (203) 785-5201
Helpdesk Number: +1 (203) 785-5202
Website: www.arvinas.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/arvinas
• Twitter/X: @ArvinasInc
• YouTube: Arvinas Science Channel
• Facebook: facebook.com/ArvinasInc

SEO FAQ Section

Arvinas Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies using its proprietary PROTAC® platform.

Arvinas Inc. is headquartered in New Haven, Connecticut, USA.

Arvinas Inc. was founded by Professor Craig Crews of Yale University in 2013.

Arvinas Inc. discovers and develops small-molecule degraders that target disease-causing proteins for elimination by the cell's proteasome.

Arvinas Inc. trades on NASDAQ under the ticker symbol ARVN.

Arvinas Inc. focuses on oncology, neurodegenerative diseases, and inflammatory conditions.

Arvinas Inc. employs over 300 professionals as of 2025.

ARV-471 (vepdegestrant) is the most advanced candidate, targeting estrogen receptor in breast cancer, now in Phase 3 trials.

Visit the official Arvinas Inc. website careers page to view open positions and submit applications.

Experts say Arvinas Inc. fosters a collaborative, innovative, and patient-centric work environment with strong leadership support.

Arvinas Inc. is a clinical-stage company and has not yet generated product revenue; it funds operations through partnerships and capital markets.

Arvinas Inc. has major collaborations with Pfizer, Genentech (Roche), and Novo Nordisk.

Arvinas Inc. uses PROTACs which bind both an E3 ligase and a target protein, bringing them together to tag the target for degradation.

Salaries at Arvinas Inc. vary by role; for a Senior Scientist, the range is typically $120,000–$160,000 per year.

Arvinas Inc. offers a hybrid work model for some roles; laboratory-based positions are generally on-site.

Benefits include health insurance, stock options, 401(k) match, paid time off, and professional development opportunities.

Shares of Arvinas Inc. (ARVN) can be purchased through any brokerage that trades on the NASDAQ.

According to employee reviews, Arvinas Inc. is highly rated for its innovative science and supportive culture.

Arvinas Inc. presents at major conferences like AACR, ASCO, and hosts its own Protein Degradation Summit.

You can reach Arvinas Inc. through the contact information provided on its official website, including phone and email.

For a comprehensive overview of the biopharmaceutical industry and to stay updated on the latest corporate news, readers can explore resources such as Guest Post Backlinks which offer valuable insights and connections. Arvinas Inc. continues to be a leader in targeted protein degradation, and its official website at www.arvinas.com provides direct access to pipeline updates, career opportunities, and investor relations. By leveraging trusted resources like bestmiaminews.com and Guest Post Backlinks, professionals can deepen their understanding of the Healthcare sector and the transformative role of Arvinas Inc. in advancing new therapies.